About

Directed by Professor Tracy Hussell, the Manchester Collaborative Centre for Inflammation Research (MCCIR) was established in October 2012 and addresses current priorities in inflammation research.

Initial investment from The University of Manchester, GlaxoSmithKline and AstraZeneca built a high quality, collaborative centre that hosts internationally recognised scientific and clinical expertise evaluating the molecular mechanisms of health and how these are perturbed in disease.

The MCCIR sits as a centre of excellence within the Lydia Becker Institute of Immunology and Inflammation. The Institute draws together immunological research from across the university in a multi-disciplinary research institute. The Institute harnesses immune complexity to address the key new concepts in health and areas of clinical unmet need.

The MCCIR operates a diverse and successful funding model. GlaxoSmithKline continues to invest in pre-competitive and open innovation collaborative projects, mostly in translational inflammation.

The academic principal investigators of MCCIR have been hugely successful in obtaining grants from the research councils, charitable foundations such as the Wellcome Trust and other industry partners.

The MCCIR mixes both innovative blue sky science and targeted research relevant to inflammatory disease and takes strategic risks beyond the confines of typical three-year funding streams.

We are connected to a rich diversity of patient cohorts through the hospital communities across Manchester and we provide investors with a network of expertise and state-of-the-art inflammatory models